Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Lilly, Merck Sharp & Dohme Corp., Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Community Practice Connections™: 13th Annual New York Lung Cancers Symposium


Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 13th Annual New York Lung Cancers Symposium consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and brief summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Lilly, Merck Sharp & Dohme Corp., Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/Ce certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Apply testing strategies to optimize tumor characterization and inform clinical decision-making for the management of patients with lung cancers
  • Integrate prognostic and biomarker findings to inform personalized treatment planning and sequencing for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer
  • Evaluate recent and emerging evidence concerning single-agent and combination immunotherapeutic approaches to managing lung cancers
  • Explain current and emerging oncogene-driven NSCLC subtypes in the context of optimizing therapeutic sequencing for multiple lines of therapy
  • Determine optimized strategies for patients without mutations, including the role of chemotherapies and antiangiogenic strategies in these settings
  • Assess proactive strategies to plan for and mitigate the impact of treatment-related toxicities in the care of patients with lung cancers

Faculty, Staff, and Planners' Disclosures

Faculty

D. Ross Camidge, MD, PhD
Professor with Tenure
Division of Medical Oncology –Joyce Zeff Chair in Lung Cancer Research
University of Colorado, Denver, School of Medicine
Denver, CO
 

Disclosures: Consultant: AstraZeneca, Takeda, Arrys/Kyn, Regeneron, Hengrui, G1 Therapeutics (DSMB), Daichii Sankyo (ILD Adjudication Committee), Hansoh (SRC), Biothera (DSMB), Ribon, Bristol-Myers Squibb, Blueprint, Roche/Genentech, Inivata

Nasser H. Hanna, MD
Professor of Medicine
Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research
Indiana University Simon Cancer Center
Indianapolis, IN
 

Disclosures: Grant/Research Support: Merck, Bristol-Myers Squibb

Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosures: Consultant: AstraZeneca

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Albert Einstein College of Medicine
Deputy Director, Albert Einstein Cancer Center
Bronx, NY

Disclosures: Grant/Research Support: National Cancer Institute; Consultant: GlaxoSmithKline, AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Shareholder: Adgero, Stelexis

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/Ce activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
282930
Filter By